Cumberland Pharmaceuticals CPIX Net (increase) decrease of investment in manufacturing

Other financials

Revenue$9.1M-22.0%

Gross profit$7.2M-30.0%

Operating income-$3.1M-342%

Net income-$3.3M-362%

EPS (diluted)-$0.22-375%

Cash & equivalents$11.0M-27.1%

Total debt$4.8M-7.1%

Total equity$21.6M-24.5%

Total assets$71.0M+1.5%

Operating cash flow$387.0K-90.1%

CapEx--100%

Free cash flow$387.0K-89.9%

Market cap$97.09M+138%

Enterprise value$90.91M+207%

P/S2.3×+1.3×

Gross margin82.9%-1.4pp

Operating margin-17.2%-125pp

Net margin-17.6%-103pp

FCF margin3.3%—

Return on equity-29.4%-86.3pp

Debt / equity0.2×0.0×

Current ratio1×-0.3×

Reported directly by Cumberland Pharmaceuticals in its filing.

Tagged under the XBRL concept cpix:PaymentsForProceedsFromOtherProductiveAssets.

The official record: Cumberland Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and see it in context, right in your chat.

What is Cumberland Pharmaceuticals's net (increase) decrease of investment in manufacturing?: Cumberland Pharmaceuticals (CPIX) reported net (increase) decrease of investment in manufacturing of $0 in Q1 2026.